MetaCap

Coya Therapeutics (COYA) vs Fortress Biotech (FBIO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Fortress Biotech (FBIO) has outperformed Coya Therapeutics (COYA) over the past year, losing 26.6% versus a loss of 50.7%. Coya Therapeutics is the larger company by market cap ($69.2 million vs $64.1 million), about 1.1 times the size. Fortress Biotech converts more of its revenue into profit, with a net margin of 10.8% versus -267.1%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

COYA-50.67%FBIO-26.64%
+75%+8%-59%
Nov 21, 20251 yearNov 20, 2026
COYA-37.74%FBIO-80.81%
+124%+14%-97%
Dec 26, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

COYA versus FBIO key metrics
MetricCOYAFBIO
Share price$2.95$1.90
Market cap$69.20M$64.11M
1-day change-1.01%+7.34%
YTD return-49.14%-48.09%
1-year return-50.67%-26.64%
5-year return—-95.52%
P/E ratio (TTM)—0.83
EPS (TTM)$-1.39$2.30
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$7.95M$63.26M
Revenue growth (YoY)+123.57%+9.69%
Net income (latest FY)$-21.23M$6.82M
Gross margin—66.92%
Operating margin-283.87%-111.00%
Net margin-267.14%10.77%
52-week high$6.62$4.53
52-week low$2.72$1.64
Distance from 52-week high-55.44%-58.06%
Analyst consensusstrong_buynone
Avg. price target upside+415.59%+163.16%
Average volume149.18K281.49K
Shares outstanding23.46M33.74M
Employees878
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • FBIO has outperformed COYA by 24.0 percentage points over the past year.
  • Fortress Biotech is more profitable, keeping 10.8 cents of every revenue dollar as net income versus -267.1 cents for Coya Therapeutics.
  • Coya Therapeutics grew revenue faster in its latest fiscal year (+123.57% vs +9.69%).

About Coya Therapeutics

COYA stock →

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.

Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees

About Fortress Biotech

FBIO stock →

Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma.

Health Care · Biotechnology: Pharmaceutical Preparations · 78 employees

COYA vs FBIO FAQ

Which is bigger, Coya Therapeutics or Fortress Biotech?

Coya Therapeutics (COYA) is larger, with a market capitalization of $69.20M compared with $64.11M for Fortress Biotech (FBIO).

Which stock has performed better over the past year, COYA or FBIO?

FBIO returned -26.64% over the past 12 months, compared with -50.67% for COYA (price return, excluding dividends). Past performance does not predict future results.

Are Coya Therapeutics and Fortress Biotech in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons